2-[(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-N-ethylacetohydrazide

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-[(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-N-ethylacetohydrazide
• 化学式: C₁₄H₂₁N₇O₅
• 分子量: 367.36
• InChiKey: NQPSJGBKLXYZMC-FRJWGUMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  186
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• CELL-PENETRATING OLIGONUCLEOTIDES
  申请人：Oligomer Sciences AB

  公开号：EP2961757A1

  公开（公告）日：2016-01-06
• [EN] CELL-PENETRATING OLIGONUCLEOTIDES<br/>[FR] OLIGONUCLÉOTIDES PÉNÉTRANT LES CELLULES
  申请人：OLIGOMER SCIENCES AB

  公开号：WO2014131892A1

  公开（公告）日：2014-09-04

  The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2' position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.